Mablink will take the opportunity to meet with pharmaceutical companies and investors during MEET2WIN, the European oncology partnering convention entirely dedicated to open innovation, collaborative research and technology transfer. Two vibrant days dedicated to oncology and innovation.
Mablink Bioscience will present the latest technological advances of its ADC platform for highly-loaded & highly hydrophilic ADCs
Mablink Bioscience is looking forward to the 10th edition of the World ADC congress in London, Europe’s longest standing and most comprehensive forum in the ADC field.
Mablink is adopting Agatha’s solution, a global leader in quality and content management solutions for life sciences.
Discover Mablink’s ADC platform and meet our COO Valérie Attuil-Audenis and our CEO Jean-Guillaume Lafay at BioFIT Event on December 10 and 11 in Marseille
Mablink receives the support of the Canceropole CLARA to push forward the development of its ADC platform
Mablink receives the iLab 2019 award in the presence of French Minister of Higher Education, Research and Innovation, Mrs Frédérique Vidal, and Bpifrance, at the innovation awards ceremony in Paris.
Photo by P. Thiessen Mablink is flying high! The French Journal des Entreprises relates in a recent article Mablink’s last fundraisings with the coming of a new investor for 125k€, …
Mablink receives a €380,000 equity investment from TTO PULSALYS to carry out the preclinical proof of concept of its ADC drug candidate MBK-102 in Non-Hodgkin’s Lymphoma.
After having earned the #FrenchTechSeed label in the middle of March, Puls@lys has made an exclusive communication on our Antibody-Drug linker technology as a breakthrough innovation as well as its …
